3 recruiting, 2 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 8 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 3, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow Lupus Erythematosus, Discoid: new trials by email Literature Review of Lupus Erythematosus, Discoid trials Research Report on Lupus Erythematosus, Discoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Enpatoran - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Not yet recruiting | EMD Serono Research & Development Institute, Inc. | 404 | 2026-10-15 | 2026-09-25 |
| Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus Afimetoran, Placebo - Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus | Phase 2 / Phase 3 | Recruiting | Beeline Medicines Corporation | 390 | 2026-10-01 | 2026-10-29 |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) Enpatoran, Placebo, Standard of care (SoC) - Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 202 | 2026-04-01 | 2026-10-06 |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease Enpatoran, Placebo, Standard of care (SoC) - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 202 | 2026-03-10 | 2026-10-06 |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Anifrolumab, Placebo - Cutaneous Lupus Erythematosus | Phase 3 | Active not recruiting | AstraZeneca | 339 | 2024-06-29 | 2026-07-29 |
| A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus BIIB059 (litifilimab) - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 3 | Enrolling by invitation | Biogen | 306 | 2023-10-03 | 2026-08-04 |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Litifilimab, Placebo - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 2 / Phase 3 | Active not recruiting | Biogen | 450 | 2022-09-13 | 2026-10-23 |
| Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Pulsed-dye Laser, Sham - Lupus Erythematosus, Discoid | Phase 2 / Phase 3 | Unknown | Chulalongkorn University | 24 | 2016-12-15 | 2017-06-06 |
Lupus Erythematosus, Cutaneous (7) · Lupus Erythematosus, Systemic (4)
Connective Tissue Diseases (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Autoimmune Diseases (4) · Immune System Diseases (4) · Lupus Erythematosus, Cutaneous (1)
Standard of Care (2) · Lasers, Dye (1) · anifrolumab (1)
EMD Serono Research & Development Institute, Inc. (3) · Biogen (2) · AstraZeneca (1) · Beeline Medicines Corporation (1) · Chulalongkorn University (1)
United States (7) · Germany (6) · Brazil (5) · Bulgaria (5) · Italy (5) · Poland (5) · South Korea (5) · Spain (5) · Taiwan (5) · Canada (4) · China (4) · France (4) · Japan (4) · Slovakia (4) · Switzerland (4)
2025 (2), 2023 (1)